CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Beta (13760)
(-)
Architecture: Beta Barrel (4804)
(-)
Topology: Thrombin, subunit H (1535)
(-)
Homologous Superfamily: Trypsin-like serine proteases (1488)
(-)
Human (Homo sapiens) (615)
1A0LA:28-120,A:233-245; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE
1A2CH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THROMBIN INHIBITED BY AERUGINOSIN298-A FROM A BLUE-GREEN ALGA
1A3BH:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1
1A3EH:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2
1A46H:28-120,H:233-245; H:16-27,H:121-232THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR
1A4WH:28-120,H:233-239; H:16-27,H:121-232CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE
1A5GH:28-120,H:233-245; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1A5HA:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE
1A61H:28-120,H:233-245; H:16-27,H:121-232THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
1A7SA:1-12,A:108-207; A:13-107,A:208-221ATOMIC RESOLUTION STRUCTURE OF HBP
1ABIH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS
1ABJH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS
1AD8H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
1AE5A:1-12,A:108-207; A:13-107,A:208-221HUMAN HEPARIN BINDING PROTEIN
1AE8H:28-120,H:233-246; H:16-27,H:121-232HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP
1AFEH:28-120,H:233-246; H:16-27,H:121-232HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP
1AHTH:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION
1AI8H:28-120,H:233-243; H:16-27,H:121-232HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG
1AIXH:28-120,H:233-243; H:16-27,H:121-232HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL
1AU8A:16-27,A:121-232; A:28-120,A:233-244HUMAN CATHEPSIN G
1AUTC:28-120,C:233-243; C:16-27,C:121-232HUMAN ACTIVATED PROTEIN C
1AWFH:28-120,H:233-246; H:16-27,H:121-232NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
1AWHB:28-120,B:233-246; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-246NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
1AY6H:28-120,H:233-245; H:16-27,H:121-232THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF
1B0FA:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE WITH MDL 101, 146
1B5GH:28-120,H:233-245; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1B7XB:28-120,B:233-242; B:16-27,B:121-232STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1BA8B:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES
1BB0B:28-120,B:233-244; B:16-27,B:121-232THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1BCUH:28-120,H:233-244; H:16-27,H:121-232ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN
1BDAA:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242CATALYTIC DOMAIN OF HUMAN SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR IN COMPLEX WITH DANSYL-EGR-CMK (DANSYL-GLU-GLY-ARG CHLOROMETHYL KETONE)
1BHXF:150-247; B:16-147X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357
1BIOA:28-122,A:233-243; A:16-27,A:123-232HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR
1BMLA:574-664,A:779-790; A:562-573,A:665-778; B:562-573,B:665-778; B:574-664,B:779-790COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE
1BMMH:28-120,H:233-246; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-4-[(AMINOIMINOMETHYL) AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1-OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)
1BMNH:28-120,H:233-245; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3-PIPERIDENECARBOXAMIDE (BMS-189090)
1BUIA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-244STRUCTURE OF THE TERNARY MICROPLASMIN-STAPHYLOKINASE-MICROPLASMIN COMPLEX: A PROTEINASE-COFACTOR-SUBSTRATE COMPLEX IN ACTION
1C1UH:28-120,H:239-252; H:16-27,H:121-238RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1VH:28-120,H:239-252; H:16-27,H:121-238RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C1WH:28-120,H:239-252; H:16-27,H:121-238RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES
1C4U2:28-120,2:233-246; 2:16-27,2:121-232SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1C4V2:28-120,2:233-246; 2:16-27,2:121-232SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
1C4Y2:28-120,2:233-245; 2:16-27,2:121-232SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS
1C5LH:28-120,H:233-245; H:16-27,H:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5MD:16-27,D:121-232; D:28-120,D:233-250STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5NH:28-120,H:233-245; H:16-27,H:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5OH:28-120,H:233-245; H:16-27,H:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5WB:28-120,B:233-245; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5XB:28-120,B:233-245; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5YB:28-120,B:233-245; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1C5ZB:28-120,B:233-242; B:16-27,B:121-232STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1CA8B:28-120,B:233-243; B:16-27,B:121-232THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1CGHA:16-27,A:121-232; A:28-120,A:233-244HUMAN CATHEPSIN G
1CVWH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF ACTIVE SITE-INHIBITED HUMAN COAGULATION FACTOR VIIA (DES-GLA)
1D3DB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4
1D3PB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3
1D3QB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2
1D3TB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1
1D4PB:49-153,B:281-292; B:37-48,B:154-280CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR
1D6WA:28-120,A:233-243; A:16-27,A:121-232STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
1D9IA:28-120,A:233-244; A:16-27,A:121-232STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
1DANH:16-27,H:121-232; H:28-120,H:233-246COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR
1DDJA:574-664,A:779-791; A:562-573,A:665-778; B:562-573,B:665-778; C:562-573,C:665-778; D:562-573,D:665-778; B:574-664,B:779-791; C:574-664,C:779-791; D:574-664,D:779-791CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN
1DE7H:28-120,H:233-243; H:16-27,H:121-232; K:16-27,K:121-232; K:28-120,K:233-245INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
1DFPA:28-122,A:233-243; B:28-122,B:233-243; A:16-27,A:123-232; B:16-27,B:123-232FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE
1DICA:28-122,A:233-243; A:16-27,A:123-232STRUCTURE OF 3,4-DICHLOROISOCOUMARIN-INHIBITED FACTOR D
1DITH:28-120,H:233-246; H:16-27,H:121-232COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN
1DLEA:1-120,A:233-248; B:1-120,B:233-248; B:121-229; A:121-229FACTOR B SERINE PROTEASE DOMAIN
1DM4B:28-120,B:233-246; B:16-27,B:121-232SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16)
1DOJA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN*RWJ-51438 COMPLEX AT 1.7 A
1DSTA:28-122,A:233-243; A:16-27,A:123-232MUTANT OF FACTOR D WITH ENHANCED CATALYTIC ACTIVITY
1DSUA:28-122,A:233-243; B:28-122,B:233-242; A:16-27,A:123-232; B:16-27,B:123-232HUMAN FACTOR D, COMPLEMENT ACTIVATING ENZYME
1DVAH:16-27,H:121-232; I:16-27,I:121-232; H:28-120,H:233-246; I:28-120,I:233-246CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE PEPTIDE EXOSITE INHIBITOR E-76 AND COAGULATION FACTOR VIIA
1DWBH:28-120,H:233-244; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWCH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWDH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DWEH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1DX5M:28-120,M:233-246; M:16-27,M:121-232; N:16-27,N:121-232; O:16-27,O:121-232; P:16-27,P:121-232; N:28-120,N:233-246; O:28-120,O:233-246; P:28-120,P:233-246CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
1E0FE:28-120,E:233-244; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; D:28-120,D:233-245; F:28-120,F:233-246CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
1EAWA:28-120,A:233-244; C:28-120,C:233-244; A:16-27,A:121-232; C:16-27,C:121-232CRYSTAL STRUCTURE OF THE MTSP1 (MATRIPTASE)-BPTI (APROTININ) COMPLEX
1EAXA:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF MTSP1 (MATRIPTASE)
1EB1H:28-120,H:233-245; H:16-27,H:121-232COMPLEX STRUCTURE OF HUMAN THROMBIN WITH N-METHYL-ARGININE INHIBITOR
1EJNA:28-120,A:233-244; A:16-27,A:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX
1ELVA:423-436,A:534-655; A:437-532,A:656-664CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COMPLEMENT C1S PROTEASE
1EOJA:28-120,A:233-243; A:16-27,A:121-232DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1EOLA:28-120,A:233-243; A:16-27,A:121-232DESIGN OF P1' AND P3' RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1EZQA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515
1EZXC:42-245CRYSTAL STRUCTURE OF A SERPIN:PROTEASE COMPLEX
1F0RA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815
1F0SA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208707
1F5KU:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEX
1F5LA:28-120,A:233-242; A:16-27,A:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX
1F92A:28-120,A:233-244; A:16-27,A:121-232UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX
1FAKH:16-27,H:121-232; H:28-120,H:233-246HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT
1FAXA:16-27,A:121-232; A:28-120,A:233-245COAGULATION FACTOR XA INHIBITOR COMPLEX
1FDPA:28-122,A:233-242; B:28-122,B:233-240; C:28-122,C:233-240; D:28-122,D:233-240; A:17-27,A:123-232; B:22-27,B:123-232; D:22-27,D:123-232; C:22-27,C:123-232PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D
1FJSA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA
1FPCH:28-120,H:233-243; H:16-27,H:121-232ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
1FPHH:28-120,H:233-247; H:16-27,H:121-232THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY
1FQ3A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-244; B:28-120,B:233-244CRYSTAL STRUCTURE OF HUMAN GRANZYME B
1FUJA:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-243; B:28-120,B:233-243; C:28-120,C:233-243; D:28-120,D:233-243PR3 (MYELOBLASTIN)
1FV9A:13-118,A:235-244; A:1-12,A:119-234CRYSTAL STRUCTURE OF HUMAN MICROUROKINASE IN COMPLEX WITH 2-AMINO-5-HYDROXY-BENZIMIDAZOLE
1FXYA:16-27,A:121-232; A:28-120,A:233-246COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1FY1A:1-12,A:108-207; A:13-107,A:208-221[R23S,F25E]HBP, A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37)
1FY3A:1-12,A:108-207; A:13-107,A:208-221[G175Q]HBP, A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37)
1G2LA:16-27,A:122-237; A:28-121,A:238-250FACTOR XA INHIBITOR COMPLEX
1G2MA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA INHIBITOR COMPLEX
1G30B:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1G32B:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1G37A:28-120,A:233-243; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE
1GHVH:28-120,H:233-244; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHWH:28-120,H:233-242; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHXH:28-120,H:233-244; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GHYH:28-120,H:233-244; H:16-27,H:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI7B:28-120,B:233-242; B:16-27,B:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI8B:28-120,B:233-242; B:16-27,B:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GI9B:28-120,B:233-242; B:16-27,B:121-232A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1GJ4H:28-120,H:233-245; H:16-27,H:121-232SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
1GJ5H:28-120,H:233-244; H:16-27,H:121-232SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN
1GJ7B:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJ8B:28-120,B:233-242; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJ9B:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJAB:28-120,B:233-242; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJBB:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJCB:28-120,B:233-243; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GJDB:28-120,B:233-242; B:16-27,B:121-232ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1GPZA:560-675; B:560-675; B:461-558,B:676-681; A:461-558,A:676-681; A:442-460; B:442-460THE CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
1GVLA:16-27,A:121-232; A:28-120,A:233-244HUMAN PROKALLIKREIN 6 (HK6)/ PROZYME/ PROPROTEASE M/ PRONEUROSIN
1H1BA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-243; B:28-120,B:233-243CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE COMPLEXED WITH AN INHIBITOR (GW475151)
1H4WA:16-27,A:121-232; A:28-120,A:233-245STRUCTURE OF HUMAN TRYPSIN IV (BRAIN TRYPSIN)
1H8DH:28-120,H:233-245; H:16-27,H:121-232X-RAY STRUCTURE OF THE HUMAN ALPHA-THROMBIN COMPLEX WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
1H8IH:28-120,H:233-245; H:16-27,H:121-232X-RAY CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
1HAGE:28-120,E:233-247; E:16-27,E:121-232THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HAHH:28-120,H:233-246; H:16-27,H:121-232THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HAIH:28-120,H:233-246; H:16-27,H:121-232THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
1HBTH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH A PEPTIDYL PYRIDINIUM METHYL KETONE CONTAINING BIVALENT INHIBITOR
1HCGA:16-27,A:121-232; A:28-120,A:233-251STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION
1HDTH:28-120,H:233-247; H:16-27,H:121-232STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN
1HFDA:28-122,A:233-243; A:16-27,A:123-232HUMAN COMPLEMENT FACTOR D IN A P21 CRYSTAL FORM
1HGTH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
1HLTH:28-120,H:233-243; H:16-27,H:121-232; K:16-27,K:121-232; K:28-120,K:233-243THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN
1HNEE:16-27,E:121-232; E:28-120,E:233-243STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A PEPTIDE CHLOROMETHYL KETONE INHIBITOR AT 1.84-ANGSTROMS RESOLUTION
1HXEH:28-120,H:233-243; H:16-27,H:121-232SERINE PROTEASE
1HXFH:28-120,H:233-243; H:16-27,H:121-232HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT
1IAUA:16-27,A:121-232; A:28-120,A:233-244HUMAN GRANZYME B IN COMPLEX WITH AC-IEPD-CHO
1IHSH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6
1IHTH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6
1IOEA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55532
1IQEA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55590
1IQFA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55165
1IQGA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55159
1IQHA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55143
1IQIA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55125
1IQJA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55124
1IQKA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55113
1IQLA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54476
1IQMA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54471
1IQNA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55192
1J9CH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX
1JBUH:20-27,H:121-232; H:28-120,H:233-246COAGULATION FACTOR VII ZYMOGEN (EGF2/PROTEASE) IN COMPLEX WITH INHIBITORY EXOSITE PEPTIDE A-183
1JMOH:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF THE HEPARIN COFACTOR II-S195A THROMBIN COMPLEX
1JOUB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; F:16-27,F:121-232; D:28-120,D:233-245; F:28-120,F:233-245CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
1JWTA:49-153,A:275-287; A:16-48,A:154-274CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR
1K21H:28-120,H:233-243; H:16-27,H:121-232HUMAN THROMBIN-INHIBITOR COMPLEX
1K22H:28-120,H:233-245; H:16-27,H:121-232HUMAN THROMBIN-INHIBITOR COMPLEX
1KLIH:16-27,H:121-232; H:28-120,H:233-246COFACTOR-AND SUBSTRATE-ASSISTED ACTIVATION OF FACTOR VIIA
1KLJH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF UNINHIBITED FACTOR VIIA
1KLTA:16-27,A:121-232; A:28-120,A:233-245CRYSTAL STRUCTURE OF PMSF-TREATED HUMAN CHYMASE AT 1.9 ANGSTROMS RESOLUTION
1KSNA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH FXV673
1KTSB:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1KTTB:28-120,B:233-245; B:16-27,B:121-232THROMBIN INHIBITOR COMPLEX
1KYE  [entry was replaced by entry 3LIW without any CATH domain information]
1KYNA:16-27,A:121-232; B:316-327,B:421-532; B:328-420,B:533-544; A:28-120,A:233-243CATHEPSIN-G
1L2EA:16-27,A:121-232; A:28-120,A:233-243HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR
1L4DA:574-664,A:779-790; A:562-573,A:665-778CRYSTAL STRUCTURE OF MICROPLASMINOGEN-STREPTOKINASE ALPHA DOMAIN COMPLEX
1L4ZA:574-664,A:779-790; A:562-573,A:665-778X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF MICROPLASMINOGEN WITH ALPHA DOMAIN OF STREPTOKINASE IN THE PRESENCE CADMIUM IONS
1LCYA:6-109,A:204-210; A:110-202CRYSTAL STRUCTURE OF THE MITOCHONDRIAL SERINE PROTEASE HTRA2
1LHCH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH
1LHDH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH
1LHEH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH
1LHFH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH
1LHGH:28-120,H:233-244; H:16-27,H:121-232HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH
1LMWB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
1LO6A:16-27,A:121-232; A:28-120,A:233-243HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR AT 1.56 A RESOLUTION
1LPGB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.
1LPKB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
1LPZB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.
1LQDB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
1LTOA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN ALPHA1-TRYPTASE
1MD7A:449-460,A:560-675; A:461-558,A:676-683MONOMERIC STRUCTURE OF THE ZYMOGEN OF COMPLEMENT PROTEASE C1R
1MD8A:447-460,A:560-675; A:461-558,A:676-683MONOMERIC STRUCTURE OF THE ACTIVE CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
1MH0A:28-120,A:233-243; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-243CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
1MQ5A:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL) AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1MQ6A:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL) AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2-OXAZOLYL) METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1MU6B:28-120,B:233-244; B:16-27,B:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH L-378,622
1MU8B:28-120,B:233-244; B:16-27,B:121-232THROMBIN-HIRUGEN_L-378,650
1MUEB:28-120,B:233-244; B:16-27,B:121-232THROMBIN-HIRUGEN-L405,426
1MZAA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
1MZDA:28-120,A:233-245; A:16-27,A:121-232CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
1NFUA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747
1NFWA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685
1NFXA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944
1NFYA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095
1NM6A:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR AT 1.8A
1NN6A:18-27,A:123-228; A:28-122,A:229-240HUMAN PRO-CHYMASE
1NO9H:28-120,H:233-245; H:16-27,H:121-232DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATING NOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X-RAY CRYSTALLOGRAPHIC STUDIES.
1NRNH:28-120,H:233-242; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NROH:28-120,H:233-244; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRPH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRQH:28-120,H:233-238; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRRH:28-120,H:233-244; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRSH:28-120,H:233-245; H:16-27,H:121-232CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NT1A:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR
1NU7B:28-120,B:233-245; B:16-27,B:121-232; F:16-27,F:121-232; F:28-120,F:233-245STAPHYLOCOAGULASE-THROMBIN COMPLEX
1NU9D:28-120,D:233-245; A:16-27,A:121-232; D:16-27,D:121-232; A:28-120,A:233-246STAPHYLOCOAGULASE-PRETHROMBIN-2 COMPLEX
1NY22:28-120,2:233-245; 2:16-27,2:121-232HUMAN ALPHA THROMBIN INHIBITED BY RPPGF AND HIRUGEN
1NZQH:28-120,H:233-244; H:16-27,H:121-232D-PHE-PRO-ARG-TYPE THROMBIN INHIBITOR
1O0DH:28-120,H:233-244; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH A D-PHE-PRO-ARG-TYPE INHIBITOR AND A C-TERMINAL HIRUDIN DERIVED EXO-SITE INHIBITOR
1O2GH:28-120,H:233-245; H:16-27,H:121-232ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3PB:28-120,B:233-243; B:16-27,B:121-232ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O5AB:28-120; B:16-27,B:121-243DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5BB:28-120; B:16-27,B:121-242DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5CB:28-120; B:16-27,B:121-243DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5DH:16-27,H:121-232; H:28-120,H:233-246DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5EH:16-27,H:121-230; H:28-120,H:231-255DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5FH:16-27,H:121-230; H:28-120,H:231-255DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5GH:28-120,H:233-245; H:16-27,H:121-232DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1OOKB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND HUMAN ALPHA-THROMBIN
1OP8A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; E:16-27,E:121-232; F:16-27,F:121-232; A:28-120,A:233-246; B:28-120,B:233-246; C:28-120,C:233-246; D:28-120,D:233-246; E:28-120,E:233-246; F:28-120,F:233-246CRYSTAL STRUCTURE OF HUMAN GRANZYME A
1OPHB:16-27,B:121-232; B:28-120,B:233-245NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN
1ORFA:16-27,A:121-232; A:28-120,A:233A-244THE OLIGOMERIC STRUCTURE OF HUMAN GRANZYME A REVEALS THE MOLECULAR DETERMINANTS OF SUBSTRATE SPECIFICITY
1OWDA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWEA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWHA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWIA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWJA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWKA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OYTH:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR
1P0SH:16-27,H:121-232; H:28-120,H:233-245CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEX WITH ECOTIN M84R
1P57B:16-27,B:121-230; B:28-120,B:231-254EXTRACELLULAR DOMAIN OF HUMAN HEPSIN
1P8VC:13-117,C:245-257; C:1-12,C:118-244CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A
1PJPA:16-27,A:121-232; A:28-120,A:233-245THE 2.2 A CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SUCCINYL-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
1PPBH:28-120,H:233-247; H:16-27,H:121-232THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT
1PPFE:16-27,E:121-232; E:28-120,E:233-243X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN LEUKOCYTE ELASTASE (PMN ELASTASE) AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR
1Q3XA:459-550,A:675-682; B:459-550,B:675-682; A:445-458,A:552-674; B:445-458,B:552-674CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-2
1QBVH:28-120,H:233-244; H:16-27,H:121-232CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR
1QFKH:153-164,H:261-381; H:165-260,H:382-395STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION
1QHRB:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ1B:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ6B:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ7B:28-120,B:233-246; B:16-27,B:121-232NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QRZA:574-664,A:779-791; A:562-573,A:665-778; B:562-573,B:665-778; C:562-573,C:665-778; D:562-573,D:665-778; B:574-664,B:779-791; C:574-664,C:779-791; D:574-664,D:779-791CATALYTIC DOMAIN OF PLASMINOGEN
1QURH:28-120,H:233-245; H:16-27,H:121-232HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR
1RD3B:28-120,B:233-244; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-2442.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1RFNA:16-27,A:121-232; A:28-120,A:233-245HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE
1RIWC:185-286; B:37-183THROMBIN IN COMPLEX WITH NATURAL PRODUCT INHIBITOR OSCILLARIN
1RJXB:574-664,B:779-790; B:562-573,B:665-778HUMAN PLASMINOGEN CATALYTIC DOMAIN, K698M MUTANT
1RRKA:452-570; A:571-739CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B
1RS0A:452-570; A:571-739CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH DI-ISOPROPYL-PHOSPHATE (DIP)
1RTFB:28-120,B:233-242; B:16-27,B:121-232COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA]
1RTKA:452-570; A:571-739CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH 4-GUANIDINOBENZOIC ACID
1SB1H:28-120,H:233-244; H:16-27,H:121-232NOVEL NON-COVALENT THROMBIN INHIBITORS INCORPORATING P1 4,5,6,7-TETRAHYDROBENZOTHIAZOLE ARGININE SIDE CHAIN MIMETICS
1SC8U:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-J435 COMPLEX
1SFQB:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
1SG8B:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
1SGIB:28-120,B:233-243; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-243CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
1SHHE:28-120,E:233-244; B:16-27,B:121-232; E:16-27,E:121-232; B:28-120,B:233-245SLOW FORM OF THROMBIN BOUND WITH PPACK
1SHYA:506-596,A:712-722; A:495-505,A:597-711THE CRYSTAL STRUCTURE OF HGF BETA-CHAIN IN COMPLEX WITH THE SEMA DOMAIN OF THE MET RECEPTOR.
1SI5H:506-596,H:712-728; H:495-505,H:597-711PROTEASE-LIKE DOMAIN FROM 2-CHAIN HEPATOCYTE GROWTH FACTOR
1SL3A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTUE OF THROMBIN IN COMPLEX WITH A POTENT P1 HETEROCYCLE-ARYL BASED INHIBITOR
1SPJA:28-120,A:233-245; A:16-27,A:121-232STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE
1SQAA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SQOA:13-131,A:249-258; A:1-12,A:132-248SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SQTA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SR5C:28-120,C:233-243; C:16-27,C:121-232ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE
1T31A:16-27,A:121-232; A:28-120,A:233-245A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
1T32A:16-27,A:121-232; A:28-120,A:233-244A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
1T4UH:49-153,H:275-287; H:37-48,H:154-274CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN
1T4VH:49-153,H:275-287; H:37-48,H:154-274CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN
1TA2A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 1
1TA6A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 14B
1TB6H:28-120,H:233-245; H:16-27,H:121-2322.5A CRYSTAL STRUCTURE OF THE ANTITHROMBIN-THROMBIN-HEPARIN TERNARY COMPLEX
1TBZH:28-120,H:233-246; H:16-27,H:121-232HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L-PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN
1THPB:28-120,B:233-244; B:16-27,B:121-232STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1THRH:28-120,H:233-246; H:16-27,H:121-232STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
1THSH:28-120,H:233-246; H:16-27,H:121-232STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
1TMBH:28-120,H:233-246; H:16-27,H:121-232MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A
1TMTH:28-120,H:233-245; H:16-27,H:121-232CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
1TMUH:28-120,H:233-245; H:16-27,H:121-232CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
1TOMH:28-120,H:233-245; H:16-27,H:121-232ALPHA-THROMBIN COMPLEXED WITH HIRUGEN
1TQ0B:28-120,B:233-243; D:16-27,D:121-232; B:16-27,B:121-232; D:28-120,D:233-243CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM
1TQ7B:28-120,B:233-243; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE ANTICOAGULANT THROMBIN MUTANT W215A/E217A BOUND TO PPACK
1TRNA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-246; B:28-120,B:233-246CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151
1TWXB:28-120,B:233-246; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE THROMBIN MUTANT D221A/D222K
1U6QA:13-118,A:235-244; A:1-12,A:119-234SUBSTITUTED 2-NAPHTHAMADINE INHIBITORS OF UROKINASE
1UMAH:28-120,H:233-246; H:16-27,H:121-232ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE
1UVSH:28-120,H:233-237; H:16-27,H:121-232BOVINE THROMBIN--BM51.1011 COMPLEX
1V3XA:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[6-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO(5,4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4-(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE
1VJ9U:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT464 COMPLEX
1VJAU:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT463 COMPLEX
1VR1H:28-120,H:233-241; H:16-27,H:121-232SPECIFITY FOR PLASMINOGEN ACTIVATOR INHIBITOR-1
1VZQH:28-120,H:233-255; H:16-27,H:121-232COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165
1W0YH:16-27,H:121-232; H:28-120,H:233-246TF7A_3771 COMPLEX
1W2KH:16-27,H:121-232; H:28-120,H:233-246TF7A_4380 COMPLEX
1W7GH:28-120,H:233-247; H:16-27,H:121-232ALPHA-THROMBIN COMPLEX WITH SULFATED HIRUDIN (RESIDUES 54-65) AND L-ARGININE TEMPLATE INHIBITOR CS107
1W7XH:16-27,H:121-232; H:28-120,H:233-246FACTOR7 - 413 COMPLEX
1W8BH:16-27,H:121-232; H:28-120,H:233-246FACTOR7 - 413 COMPLEX
1WAYB:28-120,B:233-246; B:16-27,B:121-232ACTIVE SITE THROMBIN INHIBITORS
1WBGB:28-120,B:233-246; B:16-27,B:121-232ACTIVE SITE THROMBIN INHIBITORS
1WQVH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE
1WSSH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4
1WTGH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE
1WU1A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE
1WUNH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE
1WV7H:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE
1XKAC:16-27,C:121-232; C:28-120,C:233-245FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1XKBC:16-27,C:121-232; C:28-120,C:233-245; D:28-120,D:233-244; D:16-27,D:121-232FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1XM1A:28-120,A:233-245; A:16-27,A:121-232NONBASIC THROMBIN INHIBITOR COMPLEX
1XMNB:28-120,B:233-246; F:16-27,F:121-232; H:16-27,H:121-232; D:16-27,D:121-232; B:16-27,B:121-232; D:28-120,D:233-246; F:28-120,F:233-246; H:28-120,H:233-246CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
1XX9B:28-121,B:234-245; A:28-121,A:234-244; B:16-27,B:122-233; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTINM84R
1XXDA:28-121,A:234-245; B:28-121,B:234-245; A:16-27,A:122-233; B:16-27,B:122-233CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH MUTATED ECOTIN
1XXFA:28-121,A:234-244; B:28-121,B:234-244; A:16-27,A:122-233; B:16-27,B:122-233CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTIN MUTANT (ECOTINP)
1YBWA:408-419,A:520-633; B:408-419,B:520-633; A:420-519,A:634-645; B:420-519,B:634-645PROTEASE DOMAIN OF HGFA WITH NO INHIBITOR
1YC0A:408-419,A:520-633; A:420-519,A:634-646SHORT FORM HGFA WITH FIRST KUNITZ DOMAIN FROM HAI-1
1YGCH:16-27,H:121-232; H:28-120,H:233-246SHORT FACTOR VIIA WITH A SMALL MOLECULE INHIBITOR
1YPEH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPGH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPJH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPKH:28-120,H:233-244; H:16-27,H:121-232THROMBIN INHIBITOR COMPLEX
1YPLH:28-120,H:233-244; H:16-27,H:121-232X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1008
1YPMH:28-120,H:233-244; H:16-27,H:121-232X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1014
1Z6EA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3'-AMINO-1,2-BENZISOXAZOL-5'-YL)-N-(4-(2'-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389)
1Z6JH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR
1Z71A:28-120,A:233-244; A:16-27,A:121-232THROMBIN AND P2 PYRIDINE N-OXIDE INHIBITOR COMPLEX STRUCTURE
1Z8GA:163-174,A:276-392; A:175-275,A:393-417CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE TRANSMEMBRANE SERINE PROTEASE HEPSIN WITH COVALENTLY BOUND PREFERRED SUBSTRATE.
1Z8IB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193A BOUND TO PPACK
1Z8JB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193P BOUND TO PPACK
1ZGIA:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 21
1ZGVA:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 2
1ZHMA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE COAGULATION FACTOR XIA IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K437 MUTANT)
1ZHPA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K505 MUTANT)
1ZHRA:28-121,A:234-245; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-C482S-K437A MUTANT)
1ZJDA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH KUNITZ PROTEASE INHIBITOR DOMAIN OF PROTEASE NEXIN II
1ZLRA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH 2-GUANIDINO-1-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ETHYL NICOTINATE
1ZMJA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH 4-(GUANIDINOMETHYL)-PHENYLBORONIC ACID
1ZMLA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE
1ZMNA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3, 2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE
1ZOMA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR
1ZPBA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE
1ZPCA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-[2-(3-CHLORO-PHENYL)-2-HYDROXY-ACETYLAMINO]-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-3-METHYL-BUTYRAMIDE
1ZPZA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH N-((R)-1-(4-BROMOPHENYL)ETHYL)UREA-ASN-VAL-ARG-ALPHA-KETOTHIAZOLE
1ZRBA:28-120,A:233-244; A:16-27,A:121-232THROMBIN IN COMPLEX WITH AN AZAFLUORENYL INHIBITOR 23B
1ZRKA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI COMPLEXED WITH 3-HYDROXYPROPYL 3-(7-AMIDINONAPHTHALENE-1-CARBOXAMIDO)BENZENESULFONATE
1ZSJA:28-121,A:234-245; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE
1ZSKA:28-121,A:234-245; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER
1ZSLA:28-121,A:234-244; A:16-27,A:122-233FACTOR XI COMPLEXED WITH A PYRIMIDINONE INHIBITOR
1ZTJA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-BENZYLAMINO-2-METHYLSULFANYL-6-OXO-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE
1ZTKA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-AMINO-6-OXO-2-M-TOLYL-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE
1ZTLA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-2-{6-OXO-5-[(QUINOLIN-8-YLMETHYL)-AMINO]-2-M-TOLYL-6H-PYRIMIDIN-1-YL}-ACETAMIDE
2A0QB:28-120,B:233-244; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-244STRUCTURE OF THROMBIN IN 400 MM POTASSIUM CHLORIDE
2A2QH:16-27,H:121-232; H:28-120,H:233-246COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+, MG2+, NA+, AND ZN2+
2A2XH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN INH12
2A45B:28-120,B:233-246; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-246CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THE CENTRAL "E" REGION OF FIBRIN
2AEIH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-3,5-DIFLURO-4-[(1-METHYL-3-PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID
2AERH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX.
2AFQD:28-120,D:233-244; D:16-27,D:121-232; B:16-27,B:121-232; B:28-120,B:233-2461.9 ANGSTROM CRYSTAL STRUCTURE OF WILD-TYPE HUMAN THROMBIN IN THE SODIUM FREE STATE
2ANKH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN AND AN EXOSITE DECAPEPTIDE
2ANMH:28-120,H:233-244; H:16-27,H:121-232TERNARY COMPLEX OF AN ORALLY ACTIVE THROMBIN INHIBITOR WITH HUMAN THROMBIN AND A C-TERMINAL HIRUDIN DERIVED EXO-SIT INHIBITOR
2ANWA:28-120,A:234-245; A:16-27,A:121-233EXPRESSION, CRYSTALLIZATION AND THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS
2ANYA:28-120,A:234-245; A:16-27,A:121-233EXPRESSION, CRYSTALLIZATION AND THE THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS
2ASUB:484-492,B:587-699; B:493-586,B:700-708CRYSTAL STRUCTURE OF THE BETA-CHAIN OF HGFL/MSP
2B5TB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-2452.1 ANGSTROM STRUCTURE OF A NONPRODUCTIVE COMPLEX BETWEEN ANTITHROMBIN, SYNTHETIC HEPARIN MIMETIC SR123781 AND TWO S195A THROMBIN MOLECULES
2B7DH:16-27,H:121-232; H:28-120,H:233-246FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION, PRECLINICAL PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY IN A BABOON THROMBOSIS MODEL
2B8OH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX
2BDGA:16-27,A:121-234; B:16-27,B:121-234; A:28-120,A:235-244; B:28-120,B:235-244HUMAN KALLIKREIN 4 COMPLEX WITH NICKEL AND P-AMINOBENZAMIDINE
2BDHA:16-27,A:121-234; B:16-27,B:121-234; C:16-27,C:121-234; D:16-27,D:121-234; A:28-120,A:235-244; B:28-120,B:235-244; C:28-120,C:235-244; D:28-120,D:235-244HUMAN KALLIKREIN 4 COMPLEX WITH ZINC AND P-AMINOBENZAMIDINE
2BDIA:16-27,A:121-234; B:16-27,B:121-234; C:16-27,C:121-234; D:16-27,D:121-234; E:16-27,E:121-234; F:16-27,F:121-234; G:16-27,G:121-234; H:16-27,H:121-234; I:16-27,I:121-234; J:16-27,J:121-234; K:16-27,K:121-234; L:16-27,L:121-234; M:16-27,M:121-234; N:16-27,N:121-234; O:16-27,O:121-234; P:16-27,P:121-234; A:28-120,A:235-244; B:28-120,B:235-244; C:28-120,C:235-244; D:28-120,D:235-244; E:28-120,E:235-244; F:28-120,F:235-244; G:28-120,G:235-244; H:28-120,H:235-244; I:28-120,I:235-244; J:28-120,J:235-244; K:28-120,K:235-244; L:28-120,L:235-244; M:28-120,M:235-244; N:28-120,N:235-244; O:28-120,O:235-244; P:28-120,P:235-244HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P-AMINOBENZAMIDINE
2BDYA:49-153,A:275-286; A:37-48,A:154-274THROMBIN IN COMPLEX WITH INHIBITOR
2BM2A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA-II TRYPTASE IN COMPLEX WITH 4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL-(5-PHENETHYL- PYRIDIN-3-YL)-METHANONE
2BMGB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50
2BOHB:16-27,B:121-232; B:28-120,B:233-245CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND "1"
2BOKA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA - CATION
2BQ6B:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21
2BQ7B:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43
2BQWB:16-27,B:121-232; B:28-120,B:233-244CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45
2BVRH:28-120,H:233-243; H:16-27,H:121-232HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET
2BZ6H:16-27,H:121-232; H:28-120,H:233-246ORALLY AVAILABLE FACTOR7A INHIBITOR
2C8WB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C8XB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C8YB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C8ZB:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C90B:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2C93B:28-120,B:233-246; B:16-27,B:121-232THROMBIN INHIBITORS
2CF8H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR
2CF9H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR
2CJIA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2CN0H:28-120,H:233-244; H:16-27,H:121-232COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED INHIBITOR
2D1JA:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR 2-[[4-[(5-CHLOROINDOL-2-YL)SULFONYL]PIPERAZIN-1-YL] CARBONYL]THIENO[3,2-B]PYRIDINE N-OXIDE
2D26C:28-120,C:233-245; C:20-27,C:121-232ACTIVE SITE DISTORTION IS SUFFICIENT FOR PROTEINASE INHIBIT SECOND CRYSTAL STRUCTURE OF COVALENT SERPIN-PROTEINASE COMPLEX
2EC9H:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607
2EI6A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-CIS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2EI7A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR TRANS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2EI8A:16-27,A:121-232; A:28-120,A:233-243FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-4-(N,N-DIMETHYLCARBAMOYL)-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL) CARBONYL]-1,2-CYCLOHEXANEDIAMINE
2F9BH:16-27,H:121-232; H:28-120,H:233-246DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS
2F9NA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN
2F9OC:28-120,C:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; D:28-120,D:233-244; A:28-120,A:233-243; B:28-120,B:233-243CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G
2F9PA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-243CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN
2FDAA:28-121,A:234-244; A:16-27,A:122-233CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COAGULATION FACTOR XIA IN COMPLEX WITH ALPHA-KETOTHIAZOLE ARGININE DERIVED LIGAND
2FEQH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS
2FESH:28-120,H:233-245; H:16-27,H:121-232ORALLY ACTIVE THROMBIN INHIBITORS
2FIRH:16-27,H:121-232; H:28-120,H:233-246CRYSTAL STRUCTURE OF DFPR-VIIA/STF
2FLBH:16-27,H:121-232; H:28-120,H:233-246DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR
2FLRH:16-27,H:121-232; H:28-120,H:233-246NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS
2FPZA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN TRYPTASE WITH 2-AMINO BENZIMIDAZOLE
2FS8A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA-TRYPTASE II WITH INHIBITOR CRA-29382
2FS9A:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA TRYPTASE II WITH INHIBITOR CRA-28427
2FWWA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA-TRYPTASE II COMPLEXED WITH 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME
2FXRA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA TRYPTASE II COMPLEXED WITH ACTIVATED KETONE INHIBITOR CRA-29382
2FZZA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-(((3R)-3-HYDROXY-1-PYRROLIDINYL) METHYL)-4-BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE
2G00A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2'-((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL)-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1-YL)BENZAMIDE
2GD4B:16-27,B:121-232; H:16-27,H:121-232; B:28-120,B:233-249; H:28-120,H:233-244CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA-PENTASACCHARIDE COMPLEX
2GDDA:28-120,A:233-244; A:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; B:28-120,B:233-244; C:28-120,C:233-244; D:28-120,D:233-244HUMAN BETA II TRYPTASE WITH INHIBITOR CRA-27592
2GDEH:28-120,H:233-244; H:16-27,H:121-232THROMBIN IN COMPLEX WITH INHIBITOR
2GP9B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF-INHIBITED CONFORMATION
2GV6A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF MATRIPTASE WITH INHIBITOR CJ-730
2GV7A:28-120,A:233-244; A:16-27,A:121-232STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR CJ-672
2H9EH:16-27,H:121-232; H:28-120,H:233-243CRYSTAL STRUCTURE OF FXA/SELECTIDE/NAPC2 TERNARY COMPLEX
2H9TH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN IN COMPLEX WITH SURAMIN
2HGTH:28-120,H:233-246; H:16-27,H:121-232STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
2HNTF:152-244; C:16-72; E:80-142CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN
2HPPH:28-120,H:233-245; H:16-27,H:121-232STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
2HPQH:28-120,H:233-245; H:16-27,H:121-232STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
2HVXA:16-27,A:121-232; A:28-120,A:233-245DISCOVERY OF POTENT, ORALLY ACTIVE, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL CHYMASE BY USING STRUCTURE-BASED DRUG DESIGN
2HWLB:28-120,B:233-245; B:16-27,B:121-232; D:16-27,D:121-232; D:28-120,D:233-245CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH FIBRINOGEN GAMMA' PEPTIDE
2J2UA:16-27,A:121-232; A:28-120,A:233-243CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J34A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J38A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J4IA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J94A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2J95A:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2JH0D:28-120,D:233-246; D:16-27,D:121-232HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JH5D:28-120,D:233-246; D:16-27,D:121-232HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JH6D:28-120,D:233-246; D:16-27,D:121-232HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JKHA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA - CATION INHIBITOR COMPLEX
2NWNA:28-120,A:233-243; A:16-27,A:121-232NEW PHARMACOPHORE FOR SERINE PROTEASE INHIBITION REVEALED BY CRYSTAL STRUCTURE OF HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR COMPLEXED WITH A CYCLIC PEPTIDYL INHIBITOR, UPAIN-1
2O8TA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q) IN COMPLEX WITH INHIBITORS
2O8UA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
2O8WA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
2OD3B:28-120,B:233-244; B:16-27,B:121-232HUMAN THROMBIN CHIMERA WITH HUMAN RESIDUES 184A, 186, 186A, 186B, 186C AND 222 REPLACED BY MURINE THROMBIN EQUIVALENTS.
2OQ5A:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF DESC1, A NEW MEMBER OF THE TYPE II TRANSMEMBRANE SERINE PROTEINASES FAMILY
2P16A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE
2P3FH:16-27,H:121-232; H:28-120,H:233-245CRYSTAL STRUCTURE OF THE FACTOR XA/NAP5 COMPLEX
2P3TB:16-27,B:121-232; B:28-120,B:233-243CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE
2P3UB:16-27,B:121-232; B:28-120,B:233-243CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663}
2P93A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE
2P94A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H-INDOLE-6-CARBOXAMIDE
2P95A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE
2PGBB:28-120,B:233-245; B:16-27,B:121-232INHIBITOR-FREE HUMAN THROMBIN MUTANT C191A-C220A
2PGQB:28-120,B:233-245; B:16-27,B:121-232HUMAN THROMBIN MUTANT C191A-C220A IN COMPLEX WITH THE INHIBITOR PPACK
2PHBA:16-27,A:121-232; A:28-120,A:233-244AN ORALLY EFFICACIOUS FACTOR XA INHIBITOR
2PKSC:185-286; B:37-183THROMBIN IN COMPLEX WITH INHIBITOR
2PR3A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA INHIBITOR
2PSXA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN
2PSYA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN AND ZINC
2PUQH:153-164,H:261-381; H:165-260,H:382-395CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR
2PW8H:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF SULFO-HIRUDIN COMPLEXED TO THROMBIN
2Q1JA:16-27,A:121-232; A:28-120,A:233-244THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS
2QXGA:16-27,A:121-234; B:16-27,B:121-234; A:28-120,A:235-246; B:28-120,B:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH ALA-ALA-PHE-CHLOROMETHYLKETONE
2QXHA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2QXIA:16-27,A:121-234; A:28-120,A:235-246HIGH RESOLUTION STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2QXJA:16-27,A:121-234; A:28-120,A:235-246CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE AND COPPER
2QY0B:447-458,B:559-674; D:447-458,D:559-674; D:459-558,D:675-686; B:459-558,B:675-686ACTIVE DIMERIC STRUCTURE OF THE CATALYTIC DOMAIN OF C1R REVEALS ENZYME-PRODUCT LIKE CONTACTS
2R0KA:16-27,A:121-230; A:28-120,A:231-243PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58
2R2MB:49-153,B:275-287; B:37-48,B:154-2742-(2-CHLORO-6-FLUOROPHENYL)ACETAMIDES AS POTENT THROMBIN INHIBITORS
2R2WU:28-120,U:233-244; U:16-27,U:121-232UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-GPPE COMPLEX
2R9PA:16-27,A:121-232; B:16-27,B:121-232; C:16-27,C:121-232; D:16-27,D:121-232; A:28-120,A:233-245; B:28-120,B:233-245; C:28-120,C:233-245; D:28-120,D:233-245HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI)
2RA0A:16-27,A:121-232; A:28-120,A:233-244X-RAY STRUCTURE OF FXA IN COMPLEX WITH 7-FLUOROINDAZOLE
2RA3A:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-246; B:28-120,B:233-246HUMAN CATIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2RG3A:16-27,A:121-232; A:28-120,A:233-243COVALENT COMPLEX STRUCTURE OF ELASTASE
2THFB:28-120,B:233-244; B:16-27,B:121-232STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
2UUFB:28-120,B:233-246; B:16-27,B:121-232THROMBIN-HIRUGEN BINARY COMPLEX AT 1.26A RESOLUTION
2UUJB:28-120,B:233-246; B:16-27,B:121-232THROMBIN-HIRUGEN-GW473178 TERNARY COMPLEX AT 1.32A RESOLUTION
2UUKB:28-120,B:233-246; B:16-27,B:121-232THROMBIN-HIRUGEN-GW420128 TERNARY COMPLEX AT 1.39A RESOLUTION
2UWLA:16-27,A:121-232; A:28-120,A:233-244SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWOA:16-27,A:121-232; A:28-120,A:233-244SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWPA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA INHIBITOR COMPLEX
2V3HH:28-120,H:233-244; H:16-27,H:121-232THROMBIN WITH 3-CYCLE NO F
2V3OH:28-120,H:233-244; H:16-27,H:121-232THROMBIN WITH 3-CYCLE WITH F
2VH0A:16-27,A:121-232; A:28-120,A:233-244STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: BIARYL PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS
2VH6A:16-27,A:121-232; A:28-120,A:233-244STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS
2VINA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIOA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIPA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIQA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIVA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIWA:28-120,A:233-245; A:16-27,A:121-232FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VNTA:22-128,A:245-254; A:10-21,A:129-244; B:10-21,B:129-244; D:10-21,D:129-244; E:10-21,E:129-244; C:8-21,C:129-244; F:8-21,F:129-244; B:22-128,B:245-254; C:22-128,C:245-254; D:22-128,D:245-254; E:22-128,E:245-254; F:22-128,F:245-254UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
2VVCA:16-27,A:121-232; A:28-120,A:233-243; B:28-120,B:233-243; B:16-27,B:121-232AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVUA:16-27,A:121-232; A:28-120,A:233-244AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVVA:16-27,A:121-232; A:28-120,A:233-244AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR
2VWLA:16-27,A:121-232; A:28-120,A:233-245AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWMA:16-27,A:121-232; B:16-27,B:121-232; A:28-120,A:233-243; B:28-120,B:233-243AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWNA:16-27,A:121-232; A:28-120,A:233-245AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWOA:16-27,A:121-232; A:28-120,A:233-245AMINOPYRROLIDINE FACTOR XA INHIBITOR
2W26A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH BAY59-7939
2W3IA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2
2W3KA:16-27,A:121-232; A:28-120,A:233-244CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1
2WPHS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT
2WPIS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE DOUBLE MUTANT
2WPJS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT, NACL-SOAKED
2WPKS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT, ETHYLENE GLYCOL-SOAKED
2WPLS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE TRIPLE MUTANT, EDTA-SOAKED
2WPMS:16-27,S:121-232; S:28-120,S:233-245FACTOR IXA SUPERACTIVE MUTANT, EGR-CMK INHIBITED
2WUBC:16-27,C:121-230; A:16-27,A:121-230; A:28-120,A:231-244; C:28-120,C:231-244CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP
2WUCA:16-27,A:121-230; A:28-120,A:231-244CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE
2XBVA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBWA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBXA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBYA:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC0A:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC4A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC5A:16-27,A:121-232; A:28-120,A:233-245FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2Z7FE:16-27,E:121-232; E:28-120,E:233-243CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN NEUTROPHIL ELASTASE WITH 1/2SLPI
2ZA5A:28-124,A:247-258; A:16-27,A:125-246; B:16-27,B:125-246; C:16-27,C:125-246; D:16-27,D:125-246; B:28-124,B:247-258; C:28-124,C:247-258; D:28-124,D:247-258CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR
2ZC9H:28-120,H:233-246; H:16-27,H:121-232THROMBIN IN COMPLEX WITH INHIBITOR
2ZCHP:28-120,P:233-245; P:16-27,P:121-232CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZCKP:28-120,P:234-246; P:16-27,P:121-233CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA, A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY
2ZCLP:28-120,P:233-245; P:16-27,P:121-232CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZDAH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1 POCKET
2ZDVH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1 POCKET
2ZEBA:13-109,A:232-243; A:1-12,A:110-231; B:1-12,B:110-231; C:1-12,C:110-231; D:1-12,D:110-231; B:13-109,B:232-243; C:13-109,C:232-243; D:13-109,D:232-243POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
2ZECA:28-124,A:247-258; A:16-27,A:125-246; B:16-27,B:125-246; C:16-27,C:125-246; D:16-27,D:125-246; B:28-124,B:247-258; C:28-124,C:247-258; D:28-124,D:247-258POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
2ZF0H:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1 POCKET
2ZFFH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S1-POCKET
2ZFPH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INIBITION
2ZFQH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZFRH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZG0H:28-120,H:233-245; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZGBH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZGCA:13-104,A:219-231; A:1-12,A:105-218CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME M
2ZGHA:13-104,A:219-231; A:1-12,A:105-218CRYSTAL STRUCTURE OF ACTIVE GRANZYME M BOUND TO ITS PRODUCT
2ZGJA:13-104,A:219-231; A:1-12,A:105-218CRYSTAL STRUCTURE OF D86N-GZMM COMPLEXED WITH ITS OPTIMAL SYNTHESIZED SUBSTRATE
2ZGXH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZHEH:28-120,H:233-246; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZHFH:28-120,H:233-245; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZHQH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZHWH:28-120,H:233-245; H:16-27,H:121-232EXPLORING THROMBIN S3 POCKET
2ZI2H:28-120,H:233-245; H:16-27,H:121-232THROMBIN INHIBITION
2ZIQH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZKSA:13-104,A:219-231; A:1-12,A:105-218STRUCTURAL INSIGHTS INTO THE PROTEOLYTIC MACHINERY OF APOPTOSIS-INDUCING GRANZYME M
2ZNKH:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
2ZO3H:28-120,H:233-246; H:16-27,H:121-232BISPHENYLIC THROMBIN INHIBITORS
2ZP0H:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE
2ZWLH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR
2ZZUH:16-27,H:121-232; H:28-120,H:233-246HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE
3B9FH:28-120,H:233-245; H:16-27,H:121-2321.6 A STRUCTURE OF THE PCI-THROMBIN-HEPARIN COMPLEX
3BEFB:28-120,B:233-245; B:16-27,B:121-232; E:16-27,E:121-232; E:28-120,E:233-245CRYSTAL STRUCTURE OF THROMBIN BOUND TO THE EXTRACELLULAR FRAGMENT OF PAR1
3BEIB:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF_INHIBITED CONFORMATION
3BF6H:28-120,H:233-246; H:16-27,H:121-232THROMBIN:SURAMIN COMPLEX
3BG8A:382-480,A:596-607; A:370-381,A:481-595CRYSTAL STRUCTURE OF FACTOR XIA IN COMPLEX WITH CLAVATADINE A
3BIUH:28-120,H:233-244; H:16-27,H:121-232HUMAN THROMBIN-IN COMPLEX WITH UB-THR10
3BIVH:28-120,H:233-244; H:16-27,H:121-232HUMAN THROMBIN-IN COMPLEX WITH UB-THR11
3BN9A:28-120,A:233-244; B:28-120,B:233-244; A:16-27,A:121-232; B:16-27,B:121-232CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2
3BSQB:16-27,B:117-227; A:16-27,A:117-227; C:16-27,C:117-227; A:28-116,A:228-238; C:28-116,C:228-238; B:28-116,B:228-237CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 PRODUCED AS A SECRETION PROTEIN IN E.COLI
3C1KA:28-120,A:233-244; A:16-27,A:121-232CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR 15
3C27B:49-153,B:275-287; B:37-48,B:154-274CYANOFLUOROPHENYLACETAMIDES AS ORALLY EFFICACIOUS THROMBIN INHIBITORS
3CENA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(2-(((5-CHLORO-2-PYRIDINYL) AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE
3CS7A:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-METHOXYPHENYL)-6-(4-(1-(PYRROLIDIN-1-YLMETHYL)CYCLOPROPYL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3D49H:28-120,H:233-245; H:16-27,H:121-232THROMBIN INHIBITION
3DA9B:49-153,B:275-288; B:37-48,B:154-274CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR
3DD2H:28-120,H:233-245; H:16-27,H:121-232CRYSTAL STRUCTURE OF AN RNA APTAMER BOUND TO HUMAN THROMBIN
3DHKH:28-120,H:233-246; H:16-27,H:121-232BISPHENYLIC THROMBIN INHIBITORS
3DT0H:28-120,H:233-246; H:16-27,H:121-232UNDERSTANDING THROMBIN INHIBITION
3DUXH:28-120,H:233-246; H:16-27,H:121-232UNDERSTANDING THROMBIN INHIBITION
3E0NB:28-120,B:233-252; B:16-27,B:121-232THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH DFFR-CHLOROMETHYL KETONE INHIBITOR
3E0PB:28-120,B:233-247; B:16-27,B:121-232THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH A COVALENT BENZOXAZOLE INHIBITOR
3E16B:28-120,B:233-248; B:16-27,B:121-232X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH BENZOXAZOLE WARHEAD PEPTIDOMIMIC, LYSINE IN P3
3E1XB:28-120,B:233-248; B:16-27,B:121-232THE CRYSTAL STRUCTURE OF APO PROSTASIN AT 1.7 ANGSTROMS RESOLUTION
3EE0B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF HUMAN THROMBIN (SPACE GROUP P2(1)2(1)2(1))
3EGKH:28-120,H:233-246; H:16-27,H:121-232KNOBLE INHIBITOR
3ELAH:153-164,H:261-381; H:165-260,H:382-395CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR
3ENSB:16-27,B:121-232; B:28-120,B:233-248; D:28-120,D:233-248; D:16-27,D:121-232CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3-CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2-PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE
3EQ0H:28-120,H:233-243; H:16-27,H:121-232THROMBIN INHIBITOR
3F68H:28-120,H:233-246; H:16-27,H:121-232THROMBIN INHIBITION
3FFGA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR (R)-6-(2'-((3-HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4, 5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3FVFB:28-120,B:233-249; B:16-27,B:121-232THE CRYSTAL STRUCTURE OF PROSTASIN COMPLEXED WITH CAMOSTAT AT 1.6 ANGSTROMS RESOLUTION
3GICB:28-120,B:233-243; B:16-27,B:121-232STRUCTURE OF THROMBIN MUTANT DELTA(146-149E) IN THE FREE FORM
3GISF:28-120,F:233-244; F:16-27,F:121-232; B:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-245; D:28-120,D:233-245CRYSTAL STRUCTURE OF NA-FREE THROMBIN IN COMPLEX WITH THROMBOMODULIN
3GOVB:461-570,B:687-699; B:449-460,B:571-686CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-1
3GYLB:28-120,B:233-248; B:16-27,B:121-232STRUCTURE OF PROSTASIN AT 1.3 ANGSTROMS RESOLUTION IN COMPLEX WITH A CALCIUM ION.
3GYMA:28-120,A:233-242; A:16-27,A:121-232; B:16-27,B:121-232; B:28-120,B:233-242STRUCTURE OF PROSTASIN IN COMPLEX WITH APROTININ
3HATH:28-120,H:233-246; H:16-27,H:121-232ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
3HKJE:28-120,E:233-246; E:16-27,E:121-232; B:16-27,B:121-232; B:28-120,B:233-247CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
3HPTD:16-27,D:121-232; B:16-27,B:121-232; B:28-120,B:233-248; D:28-120,D:233-248CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2-METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE
3IG6D:28-120,D:233-243; B:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-242LOW MOLECULAR WEIGTH HUMAN UROKINASE TYPE PLASMINOGEN ACTIVATOR 2-[6-(3'-AMINOMETHYL-BIPHENYL-3-YLOXY)-4-(3-DIMETHYLAMINO-PYRROLIDIN-1-YL)-3,5-DIFLUORO-PYRIDIN-2-YLOXY]-4-DIMETHYLAMINO-BENZOIC ACID COMPLEX
3JZ1B:28-120,B:233-246; B:16-27,B:121-232CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E:NA+ FORM
3JZ2B:28-120,B:233-245; B:16-27,B:121-232CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E* FORM
3K2UA:16-27,A:121-230; A:28-120,A:231-243CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40
3K9XB:16-27,B:121-232; D:16-27,D:121-232; B:28-120,B:233-248; D:28-120,D:233-248X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
3KCGH:16-27,H:121-232; H:28-120,H:233-245CRYSTAL STRUCTURE OF THE ANTITHROMBIN-FACTOR IXA-PENTASACCHARIDE COMPLEX
3KGPA:28-120,A:233-242; A:16-27,A:121-232CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4-(AMINOMETHYL-PHENYL)-METHANOL
3KHVA:28-120,A:233-243; A:16-27,A:121-232CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4-(AMINOMETHYL-PHENYL)-METHANOL
3KIDU:28-120,U:233-243; U:16-27,U:121-232THE CRYSTAL STRUCTURES OF 2-AMINOBENZOTHIAZOLE-BASED INHIBITORS IN COMPLEXES WITH UROKINASE-TYPE PLASMINOGEN ACTIVATOR
3KL6A:16-27,A:121-232; A:28-120,A:233-242DISCOVERY OF TETRAHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVE TAK-442: A POTENT, SELECTIVE AND ORALLY ACTIVE FACTOR XA INHIBITOR
3KQBA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE
3KQCA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2'- (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-5,6- DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQDA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-4,5- DIHYDRO-1H-1, 2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO- 1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQEA:16-27,A:121-232; A:28-120,A:233-244FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'- (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-5,6-DIHYDRO-1H- PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3LC3A:16-27,A:121-232; C:16-27,C:121-232; A:28-120,A:233-245; C:28-120,C:233-245BENZOTHIOPHENE INHIBITORS OF FACTOR IXA
3LC5A:16-27,A:121-232; A:28-120,A:233-245SELECTIVE BENZOTHIOPHINE INHIBITORS OF FACTOR IXA
4HTCH:28-120,H:233-245; H:16-27,H:121-232THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX
4THNH:28-120,H:233-246; H:16-27,H:121-232THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE.
5GDSH:28-120,H:233-246; H:16-27,H:121-232HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX
7KMEH:28-120,H:233-246; H:16-27,H:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.
8KME2:28-120,2:233-244; 2:16-27,2:121-232CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.